Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | MB | P02144 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | RARG | P13631 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12591828 | 0.94 | SMN1; SMN2 (0.73) | SMN1; SMN2HTTL3MBTL1KIF11KMT2A | |
| SCHEMBL14463078 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL19707622 | 0.84 | RAB9A (0.76) | SMN1; SMN2KIF11KMT2AMEN1CA12 | |
| SCHEMBL4579197 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KIF11KMT2A | |
| SCHEMBL861674 | 0.83 | SMN1; SMN2 (0.84) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL8643836 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KIF11KMT2A | |
| SCHEMBL8811830 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL18509213 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL19806131 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL8648800 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KIF11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024092083-A1 | SMALL MOLECULAR WEIGHT CHEMICAL COMPOUND TO ANTAGONIZE EPH-EPHRIN TETRAMERIZATION AND INHIBIT BIDIRECTIONAL SIGNALING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4360710-A2 | 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-05-01 | — | — | EP | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-113429356-B | Triazole sulfonamide derivative and application thereof in agriculture | 东莞市东阳光农药研发有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-3611158-B1 | 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2023-12-20 | — | — | EP | disclosed |
| EP-3746421-B1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-1095931-A1 | Benzidine derivatives and electrophotosensitive material using the same | KYOCERA MITA CORPORATION (JP) | 2001-05-02 | — | — | EP | disclosed |
| EP-1081138-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
| CN-1268116-A | 3-amidinoaniline derivatives activated blood coagulation factor X inhibitors, and intermediates for producing both | KISSEI PHARMACEUTICAL (JP) | 2000-09-27 | — | — | CN | disclosed |
| EP-0648737-B1 | Benzidine derivatives and electrophotosensitive material using the same | MITA INDUSTRIAL CO LTD (JP) | 1998-07-15 | — | — | EP | disclosed |
| EP-0799818-A2 | Benzidine derivatives and electrophotosensitive material using the same | MITA INDUSTRIAL CO. LTD. (JP) | 1997-10-08 | — | — | EP | disclosed |
| US-5550290-A | CHARGE TRANSFER COMPOUND | MITA INDUSTRIAL CO. LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
| EP-0648737-A1 | Benzidine derivatives and electrophotosensitive material using the same | MITA INDUSTRIAL CO. LTD. (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-4629495-A | Herbicidal 5-amino-4-cyano-1-phenylpyrazoles | MAY & BAKER LIMITED (GB) | 1986-12-16 | — | — | US | disclosed |
| EP-0034292-B1 | PROCESS FOR THE PREPARATION OF ANTHRANILIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-11-23 | — | — | EP | disclosed |
| EP-0034292-A2 | Process for the preparation of anthranilic acid derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | SMN1; SMN2 4237/4885HTT 4743/4885L3MBTL1 3238/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | SMN1; SMN2 1320/4885HTT 3156/4885L3MBTL1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.